These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12752093)

  • 1. Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
    Mori T; Yamazaki R; Ikeda Y; Okamoto S
    Br J Haematol; 2003 May; 121(4):533. PubMed ID: 12752093
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
    Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
    Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
    [No Abstract]   [Full Text] [Related]  

  • 6. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.
    Gambacorti-Passerini C; Barni R; Marchesi E; Verga M; Rossi F; Rossi F; Pioltelli P; Pogliani E; Corneo GM
    Br J Haematol; 2001 Mar; 112(4):972-4. PubMed ID: 11298594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
    Preisinger C; Schwarz JP; Bleijerveld OB; Corradini E; Müller PJ; Anderson KI; Kolch W; Scholten A; Heck AJ
    Leukemia; 2013 Mar; 27(3):743-6. PubMed ID: 22976128
    [No Abstract]   [Full Text] [Related]  

  • 12. Doctors condemn NICE's guidance on leukaemia drug.
    Mayor S
    BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
    [No Abstract]   [Full Text] [Related]  

  • 13. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 14. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
    Westfall DE; Zhang L; Song S; Lee S
    Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
    Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
    Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
    Stagno F; Stella S; Berretta S; Massimino M; Antolino A; Giustolisi R; Messina A; Di Raimondo F; Vigneri P
    Leuk Res; 2008 Apr; 32(4):673-4. PubMed ID: 17889935
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathobiology of lymphoid and myeloid blast crisis and management issues.
    Ilaria RL
    Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.